|
|
||||||||
Department of Neurological Sciences, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.
long-acting levodopa/carbidopa combination (CR-CSinemet) was compared with traditional levodopa/carbidopa (Sinemet) open label in 20 patients with Parkinson's disease and "wearing-off" phenomena. After 4 to 6 weeks of therapy with CR-4-Sinemet, the number of daily doses of medication dropped significantly compared with traditional Sinemet, disability improved, and "on" time increased. In nine patients receiving CR-4-Sinemet for 3 months, the number of daily doses and the on time without chorea remained significantly improved. CR-4-Sinemet peaked in plasma after 2 hours, and moderately high levels remained at 4 hours after the dose. Side effects were similar between traditional Sinemet and CR-4 Sinemet.
Address correspondence and reprint requests to Dr. Goetz, Department of Neurological Sciences, Rush-Presbyterian St. Luke's Medical Center, 1753 West Congress Parkway, Chicago, IL 60612.
Received June 12, 1986. Accepted for publication in find form August 27, 1986.
This article has been cited by other articles:
![]() |
R. B. Dewey Jr. Management of motor complications in Parkinson's disease Neurology, March 23, 2004; 62(6_suppl_4): S3 - S7. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |